Literature DB >> 30288950

Imbalances in tissue inhibitors of metalloproteinases differentiate choroidal neovascularization from geographic atrophy.

Marie Krogh Nielsen1,2, Yousif Subhi1,2, Christopher Rue Molbech1,2, Line Lynge Nilsson2,3, Mogens Holst Nissen4, Torben Lykke Sørensen1,2.   

Abstract

PURPOSE: Tissue inhibitor of metalloproteinase (TIMP) is known to play a role in age-related macular degeneration (AMD). We wished to investigate alterations in different late stages of AMD: neovascular AMD and geographic atrophy (GA).
METHODS: This was a prospective case-control study. A total of 125 participants were included consecutively during a period of 18 months. We included 46 patients with neovascular AMD, 46 patients with GA without any sign of choroidal neovascularization in either eye, and 33 healthy aged controls. Patients with immune-affecting disorders were not included. Commercial immunoassay kits were used to quantify levels of TIMP-1, TIMP-3, MMP-2 and MMP-9 in blood plasma.
RESULTS: We found that patients with neovascular AMD had lower plasma concentration of TIMP-3 (p = 0.028) than healthy controls. Patients with GA had higher plasma levels of TIMP-1 (p < 0.001) and MMP-9 (p = 0.022) compared to healthy controls. Also, we found that TIMP-1 levels in patients with GA increased with age (Spearman's rho = 0.04, p = 0.006).
CONCLUSION: Matrix metalloproteinases (MMPs) and TIMPs, which are known to be involved in age-related changes in Bruch's membrane, are significantly altered systemically, suggesting the presence of an imbalance in the homeostasis of the extracellular matrix. These imbalances may explain differences in the clinical manifestation of late AMD.
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  age-related macular degeneration; choroidal neovascularization; geographic atrophy; matrix metalloproteinases; tissue inhibitors of metalloproteinases

Mesh:

Substances:

Year:  2018        PMID: 30288950     DOI: 10.1111/aos.13894

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  11 in total

1.  Biomarkers for Nonexudative Age-Related Macular Degeneration and Relevance for Clinical Trials: A Systematic Review.

Authors:  Vivienne Fang; Maria Gomez-Caraballo; Eleonora M Lad
Journal:  Mol Diagn Ther       Date:  2021-08-25       Impact factor: 4.074

Review 2.  The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms.

Authors:  Miłosz Caban; Katarzyna Owczarek; Urszula Lewandowska
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

Review 3.  Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).

Authors:  Luis García-Onrubia; Fco Javier Valentín-Bravo; Rosa M Coco-Martin; Rogelio González-Sarmiento; J Carlos Pastor; Ricardo Usategui-Martín; Salvador Pastor-Idoate
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

4.  The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Charlotte Liisborg; Helle Bach Søndergaard; Finn Sellebjerg; Torben Lykke Sørensen
Journal:  Immun Ageing       Date:  2019-08-15       Impact factor: 6.400

5.  Targeted Gene Candidates for Treatment and Early Diagnosis of Age-Related Macular Degeneration.

Authors:  Emine Cinici; Ozge Caglar; Mehmet Enes Arslan; Nilay Dilekmen; Bahadır Utlu; Adil Mardinoglu; Hasan Turkez
Journal:  Biomed Res Int       Date:  2021-02-02       Impact factor: 3.411

6.  Increased pro-MMP9 plasma levels are associated with neovascular age-related macular degeneration and with the risk allele of rs142450006 near MMP9.

Authors:  Susette Lauwen; Dirk J Lefeber; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander
Journal:  Mol Vis       Date:  2021-04-02       Impact factor: 2.367

7.  Novel Possible Protein Targets in Neovascular Age-Related Macular Degeneration: A Pilot Study Experiment.

Authors:  Bruno Nobre Lins Coronado; Felipe Bruno Santos da Cunha; Raphaela Menezes de Oliveira; Otávio de Toledo Nóbrega; Carlos André Ornelas Ricart; Wagner Fontes; Marcelo Valle de Sousa; Marcos Pereira de Ávila; Aline Maria Araújo Martins
Journal:  Front Med (Lausanne)       Date:  2022-01-27

8.  Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation.

Authors:  Jorge González-Zamora; María Hernandez; Sergio Recalde; Jaione Bezunartea; Ana Montoliu; Valentina Bilbao-Malavé; Josune Orbe; José A Rodríguez; Sara Llorente-González; Patricia Fernández-Robredo; Alfredo García-Layana
Journal:  Biomedicines       Date:  2022-06-30

9.  Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.

Authors:  Yusuke Arai; Hidenori Takahashi; Satoru Inoda; Xue Tan; Shinichi Sakamoto; Yuji Inoue; Yujiro Fujino; Hidetoshi Kawashima; Yasuo Yanagi
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

Review 10.  Potential Role of Myeloid-Derived Suppressor Cells (MDSCs) in Age-Related Macular Degeneration (AMD).

Authors:  Anu Kauppinen; Kai Kaarniranta; Antero Salminen
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.